Growing debate around the AstraZeneca vaccine has raised concerns about its efficacy and the risk of rare blood-clotting events, but current evidence offers reassuring clarity. Direct comparisons with Pfizer and Moderna are misleading because each vaccine was tested in different trials with different populations and settings. More importantly, across studies, AstraZeneca performs just as well as mRNA vaccines in preventing severe COVID-19, hospitalization, ICU admission, and death. Reports of clotting events remain extremely rare—far lower than risks associated with common activities such as oral contraceptives or air travel—and major health agencies continue to conclude that the vaccine’s benefits outweigh potential harms. Overall, available evidence does not support doubts about AstraZeneca’s effectiveness or safety.